DNAmAge

:   DNA methylation age

AA

:   age acceleration

Δ~AA~

:   change rate of age acceleration

AHM

:   antihypertensive medication

CVD

:   cardiovascular disease

CpG

:   cytosine-phosphate-guanine

BMI

:   body mass index

HDL

:   high-density lipoprotein

NAS

:   Normative Aging Study

SBP

:   systolic blood pressure

DBP

:   diastolic blood pressure

CHD

:   Coronary heart disease

IPW

:   inverse probability weighting

ADRs

:   adverse drug reactions

DNAmPhenoAge

:   DNA methylation Phenotypic age

Introduction
============

DNA methylation, a major form of epigenetic modification, is known to play an important role in aging and the development of age-related health outcomes \[[@r1],[@r2]\]. Recently, a DNA methylation-based biological age predictor, "DNA methylation age (DNAmAge)", has been established and found to be highly associated with chronological age \[[@r3]\]. The discrepancy between this epigenetic-based indicator and the chronological age has been termed age acceleration (AA), which was found to be heritable and has been used as an index of accelerated biological aging. Follow-up investigations have linked AA to lifestyle factors, environmental hazards, stressful life events, as well as all-cause mortality \[[@r4]--[@r13]\].

Several aging-related factors, including inflammation, neurohormonal disorder and endothelial dysfunction, have been found to play key mechanistic roles in the development of hypertension \[[@r14]--[@r16]\], the most common long-term medical condition among older adults that could lead to various forms of age-related health outcomes, such as cardiovascular diseases (CVD), kidney failure and dementia \[[@r17]\]. Relationships of hypertension and blood pressure with biological aging have also been studied since the introduction of DNAmAge. In 2016, Horvath et al. found that people with hypertension had a higher AA (0.5 -- 1.2 years) in comparison to controls in the Bogalusa Heart study \[[@r7]\] and a more recent study from Quach et al. showed that elevated blood pressure was also correlated with higher extrinsic and intrinsic DNAmAge \[[@r10]\].

The use of antihypertension medication (AHM) reduces the risk of adverse age-related health outcomes caused by hypertension. Specifically, observational studies, clinical trials, and systematic reviews mostly suggested that effective antihypertensive therapy greatly reduces the risk of CVD in patients with hypertension \[[@r18],[@r19]\], and may also be associated with a decreased risk of cognitive decline and incident dementia \[[@r20]\]. As DNA methylation is a durable and reversible modification, we hypothesized that the use of AHMs might also be able to influence the biological aging reflected by the epigenetic AA. Therefore, we assessed the associations of AHM use with AA and further determined whether the change of AHM use could modify the change rate of AA (Δ~AA~) during a median follow-up of 3.86 years. This investigation was carried out in the Normative Aging Study (NAS), which is an all-male longitudinal study of a cohort of older veterans living in the Greater Boston area.

RESULTS
=======

Participant characteristics
---------------------------

Characteristics of the 546 participants at each visit are shown in [Table 1](#t1){ref-type="table"}. Overall, the average age at first and second visits was 72 and 75 years, respectively. More than 60% of the participants were former smokers and less than 5% were current smokers, and the majority of participants were overweight or obese, consumed no or low amounts of alcohol, reported low physical activity and had less than 16 years of education. During a median follow-up of 3.86 years, the prevalence of hypertension increased from about 68% to 75%, stroke from nearly 6.0% to 8.6%, coronary heart disease (CHD) from 26% to 34%, diabetes from 12% to 16% and cancer from 50% to 59%. In particular, 313/374 and 383/411 participants with hypertension took the medication for elevated blood pressure at each visit, respectively. ACE inhibitors and beta blockers were the two most widely used medications. According to our definition of hypertension, the participants using AHM were considered to be have hypertension. Among the 546 participants, after the first visit, 13 stopped using any AHM and 83 started to use.

###### Characteristics of participants from the Normative Aging Study (NAS), 1999--2013 (N = 546) ^a^.

  ------------------------------------------------------------------------------ ----------------- -- ------------------
  **Characteristics**                                                            **First visit**      **Second visit**
  **Age (years)**                                                                71.6 (6.5)           75.4 (6.5)
  **DNA methylation age (Horvath, years)**                                       72.6 (6.7)           74.9 (7.1)
  **Age acceleration (Horvath, years)**                                          0.15 (5.3)           -0.05 (5.6)
  **Fasting glucose (mg/dL)**                                                    108.3 (29.2)         105.9 (21.6)
  **Total cholesterol (mg/dL)**                                                  198.8 (36.9)         180.4 (37.2)
  **Serum triglyceride (mg/dL)**                                                 139.5 (85.3)         125.8 (67.8)
  **HDL (mg/dL)**                                                                49.6 (13.4)          48.6 (13.1)
  **SBP (mm Hg)**                                                                131.5 (17.3)         124.6 (17.2)
  **Smoking status**                                                                                  
  Current smoker                                                                 23 (4.2%)            23 (4.2%)
  Former smoker                                                                  348 (63.7%)          349 (63.9%)
  Never smoker                                                                   175 (32.1%)          174 (31.9%)
  **Body mass index**                                                                                 
  Underweight or normal weight (\<25.0)                                          103 (18.9%)          130 (23.8%)
  Overweight (≥25 to \<30)                                                       299 (54.7%)          279 (51.1%)
  Obese (≥30.0)                                                                  144 (26.4%)          137 (25.1%)
  **Alcohol consumption ^b^**                                                                         
  Abstainer                                                                      114 (22.5%)          115 (25.1%)
  Low (0 to \<40 g/d)                                                            355 (70.2%)          319 (69.5%)
  Intermediate (40 to \<60 g/d)                                                  25 (4.9%)            18 (3.9%)
  High (≥60 g/d)                                                                 12 (2.4%)            7 (1.5%)
  **Physical activity (MET-hours/week) ^c^**                                                          
  Low (≤12 kcal/kg hours/week)                                                   321 (61.4%)          307 (64.2%)
  Median (12--30 kcal/kg hours/week)                                             128 (24.5%)          110 (23.0%)
  High (≥30 kcal/kg hours/week)                                                  74 (14.1%)           61 (12.8%)
  **Major diseases**                                                                                  
  Hypertension                                                                   374 (68.5%)          411 (75.3%)
  Stroke                                                                         32 (5.9%)            47 (8.6%)
  Coronary heart disease (CHD)                                                   143 (26.2%)          184 (33.7%)
  Diabetes                                                                       67 (12.3%)           89 (16.3%)
  Cancer                                                                         271 (49.6%)          323 (59.2%)
  **Use of any antihypertensive medication**                                                          
  Any                                                                            313 (57.3%)          383 (70.1%)
  Calcium channel blockers                                                       66 (12.1%)           84 (15.4%)
  ACE inhibitors                                                                 143 (26.2%)          204 (37.4%)
  Angiotensin receptor antagonists                                               21 (3.8%)            45 (8.2%)
  Alpha blockers                                                                 64 (11.7%)           90 (16.5%)
  Beta blockers                                                                  185 (33.9%)          222 (40.7%)
  Diuretics                                                                      98 (17.9%)           141 (25.8%)
                                                                                 **Both visits**      
  **Years of education ^d^**                                                                          
  ≤12 years                                                                      233 (44.5%)          
  13 -- 16 years                                                                 223 (42.6%)          
  \>16 years                                                                     68 (12.9%)           
  **Time between 1st and 2nd visits (years)**                                    3.86 (1.6)           
  **Change rate of age acceleration between visits (year/chronological year)**   -0.03 (1.3)          
  ------------------------------------------------------------------------------ ----------------- -- ------------------

a: Mean values (standard deviation) for continuous variables and n (%) for categorical variables;

b: Data missing for 40 and 87 participants at 1^st^ and 2^nd^ visits, respectively;

c: Data missing for 23 and 68 participants at 1^st^ and 2^nd^ visits, respectively;

d: Data missing for 22 participants.

Our main analyses based on the DNAmAge estimated by Horvath's algorithm. [Figure 1](#f1){ref-type="fig"} shows that the estimates were highly correlated with chronological age at each visit (Spearman coefficients \>0.6). While DNAmAge increased between the first and second visit, the overall AA of the second visit was lower than that of the first visit ([Table 1](#t1){ref-type="table"}), showing declining trajectories with a crude average Δ~AA~ of about -0.03 year/chronological year. The trajectories of AA and distributions of Δ~AA~ were illustrated in [Figure 2](#f2){ref-type="fig"}. [Figure S1](#SD4){ref-type="supplementary-material"} showed strong correlations between the AAs at both visits among those with or without hypertension at both visits (Spearman coefficients \~0.7), while for those who had hypertension or hypertension was controlled after the first visit, their correlation was slightly attenuated (Spearman coefficients = 0.53).

![Plots of predicted DNA methylation ages against chronological age.](aging-10-101626-g001){#f1}

![Individual trajectories of age acceleration (**a**) and the distribution of change rate of age acceleration (**b**).](aging-10-101626-g002){#f2}

Associations of hypertension with age acceleration and the change rate of age acceleration
------------------------------------------------------------------------------------------

We evaluated the relationship between hypertension and AA at each visit. Participants with hypertension had higher AA (years) than those without (first visit: 0.18 vs. 0.09; second visit: -0.01 vs. -0.18; p-value=0.016). The similar pattern was also observed for Δ~AA~ that participants with hypertension had a higher Δ~AA~ (year/chronological year) compared to those without (first visit: 0.03 vs. -0.14; second visit: 0.01 vs. -0.12; p-value=0.007). We further adjusted for other potential covariates at each visit in a mixed linear model to validate the observed patterns, including age, body max index (BMI), smoking status, alcohol consumption, years of education, physical activity, leukocyte distribution and the batch of microarray experiments in DNA methylation measurement. As shown in [Table S1](#SD1){ref-type="supplementary-material"}, the correlations of hypertension with AA and Δ~AA~ remained positive, albeit not statistically significant. We also tested the associations of diabetes, metabolic syndrome and commonly measured clinical biomarkers with AA and Δ~AA~ ([Table S1](#SD1){ref-type="supplementary-material"} and [S2](#SD2){ref-type="supplementary-material"}). Despite the statistically significant association between diabetes and Δ~AA~, neither metabolic syndrome nor any biomarkers were strongly associated with AA or Δ~AA~.

Cross-sectional associations of antihypertensive medication with age acceleration and the change rate of age acceleration
-------------------------------------------------------------------------------------------------------------------------

We first investigated the cross-sectional associations of AHM use with AA and Δ~AA~ at each visit. Overall, taking any AHM was significantly associated with higher AA and Δ~AA~ ([Table 2](#t2){ref-type="table"}). After adjusting for potential covariates at each visit \[age, BMI, smoking status, alcohol consumption, years of education, physical activity, leukocyte distribution, total cholesterol, high-density lipoprotein (HDL), triglycerides, fasting glucose, systolic blood pressure (SBP), hypertension, stroke, CHD, diabetes, cancer and the batch of microarray experiments in DNA methylation measurement\], people who took any AHM at each visit were about 2.3 years older than the controls in terms of AA, and their AA increased significantly during follow-up at a rate of more than 0.4 year/chronological year compared to the people who did not take any AHMs. However, the effects of specific classes of medications varied. While taking diuretics was negatively associated with AA and Δ~AA~, calcium channel blockers and alpha and beta blockers were positively correlated with AA and Δ~AA~. Angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor antagonists (ARBs) both had negative associations with Δ~AA~, but their relationships with AA were in different directions. An additional subgroup analysis was carried out among people with hypertension at each visit ([Table 3](#t3){ref-type="table"}), and the use of any AHM remained robustly associated with increased AA and Δ~AA~.

###### Cross-sectional associations of the antihypertensive medication use with age acceleration and change rate of age acceleration at first and second visits.

  --------------------------------- --------------------------------- -------------------- ------------------ ---------------------- ------- ------------------------------------- ---------------- ------- ------------------ ---------------- ------- ---------------- ---------------- -------
  **Visit**                         **Medication**                    **Medication use**   **N**              **Age acceleration**           **Change rate of age acceleration**                                                                                                          
  **Model 1 ^a^**                                                     **Model 2 ^b^**                         **Model 1**                    **Model 2**                                                                                                                                  
  Coefficients(SE)                  p-value                                                Coefficients(SE)   p-value                        Coefficients(SE)                      p-value                  Coefficients(SE)   p-value                                                    
  **First visit**                   Calcium channel blockers          No                   480                Ref                                                                  Ref                                         Ref                                       Ref              
                                    Yes                               66                   0.059 (0.723)      0.935                          0.381 (0.784)                         0.627                    0.222(0. 163)      0.175                    0.263 (0.184)    0.154            
  ACE inhibitors                    No                                403                  Ref                                               Ref                                                            Ref                                         Ref                               
                                    Yes                               143                  0.241 (0.525)      0.646                          0.281 (0.605)                         0.643                    -0.093 (0.119)     0.432                    -0.133 (0.142)   0.350            
  ARBs                              No                                525                  Ref                                               Ref                                                            Ref                                         Ref                               
                                    Yes                               21                   -0.144 (1.169)     0.902                          -0.792 (1.184)                        0.504                    -0.047 (0.265)     0.858                    -0.042 (0.279)   0.881            
  Alpha blockers                    No                                482                  Ref                                               Ref                                                            Ref                                         Ref                               
                                    Yes                               64                   1.478 (0.721)      0.041                          1.974 (0.769)                         0.011                    0.055 (0.164)      0.737                    0.041 (0.184)    0.821            
  Beta blockers                     No                                361                  Ref                                               Ref                                                            Ref                                         Ref                               
                                    Yes                               185                  1.150 (0.499)      0.022                          1.291 (0.647)                         0.047                    0.066 (0.114)      0.562                    0.075 (0.153)    0.624            
  Diuretics                         No                                448                  Ref                                               Ref                                                            Ref                                         Ref                               
                                    Yes                               98                   -0.068 (0.614)     0.911                          -0.100 (0.676)                        0.882                    -0.095 (0.138)     0.496                    -0.001 (0.159)   0.973            
  Any antihypertensive medication   No                                233                  Ref                                               Ref                                                            Ref                                         Ref                               
                                    Yes                               313                  0.935 (0.488)      0.056                          2.274 (0.860)                         0.009                    0.195 (0.111)      0.079                    0.433 (0.205)    0.035            
  **Second**                        Calcium channel blockers          No                   462                Ref                                                                  Ref                                         Ref                                       Ref              
  **visit**                                                           Yes                  84                 1.243 (0.681)          0.068                                         1.035 (0.783)    0.187                      0.214 (0.144)    0.137                    0.275 (0.163)    0.093
                                    ACE inhibitors                    No                   342                Ref                                                                  Ref                                         Ref                                       Ref              
                                                                      Yes                  204                -0.293 (0.510)         0.565                                         -0.340 (0.648)   0.601                      -0.045 (0.107)   0.671                    -0.036 (0.135)   0.791
                                    ARBs                              No                   501                Ref                                                                  Ref                                         Ref                                       Ref              
                                                                      Yes                  45                 0.790 (0.923)          0.393                                         0.697 (1.092)    0.524                      -0.247 (0.194)   0.203                    -0.314 (0.227)   0.167
                                    Alpha blockers                    No                   456                Ref                                                                  Ref                                         Ref                                       Ref              
                                                                      Yes                  90                 0.612 (0.678)          0.367                                         0.875 (0.814)    0.283                      0.034 (0.142)    0.809                    0.073 (0.170)    0.668
                                    Beta blockers                     No                   324                Ref                                                                  Ref                                         Ref                                       Ref              
                                                                      Yes                  222                1.213 (0.506)          0.017                                         1.406 (0.707)    0.047                      0.059 (0.107)    0.581                    0.155 (0.148)    0.296
                                    Diuretics                         No                   405                Ref                                                                  Ref                                         Ref                                       Ref              
                                                                      Yes                  141                -0.136 (0.563)         0.809                                         -0.047 (0.683)   0.945                      -0.029 (0.118)   0.809                    -0.050 (0.142)   0.724
                                    Any antihypertensive medication   No                   163                Ref                                                                  Ref                                         Ref                                       Ref              
                                                                      Yes                  383                0.659 (0.543)          0.226                                         2.313 (1.096)    0.035                      0.097 (0.114)    0.396                    0.467 (0.229)    0.042
  --------------------------------- --------------------------------- -------------------- ------------------ ---------------------- ------- ------------------------------------- ---------------- ------- ------------------ ---------------- ------- ---------------- ---------------- -------

a: Model 1: Adjusted for covariates at each visit: age + leukocyte distribution (Houseman algorithm) + random effect (batch effect of DNA methylation measurement). Age acceleration was additionally adjusted for in the model for the change rate of age acceleration;

b: Model 2: Model 1 + BMI + smoking status + alcohol consumption + physical activity + years of education + total cholesterol + HDL + triglycerides + fasting glucose + SBP + hypertension + stroke + CHD + diabetes + cancer.

###### Cross-sectional associations of antihypertensive medication use with age acceleration and change of age acceleration at first and second visits among the subpopulation who had hypertension.

  --------------------------------- --------------------------------- -------------------- ---------------- ------------------------- --------- ---------------------------------------- ------------------ ---------
  **Visit**                         **Medication**                    **Medication use**   **N**            **Age acceleration^a^**             **Change rate of age acceleration^b^**                      
                                                                                                            Coefficients(SE)          p-value                                            Coefficients(SE)   p-value
  **First visit**                   Calcium channel blockers          No                   308              Ref                                                                          Ref                
                                    Yes                               66                   -0.390 (0.816)   0.633                               0.346 (0.202)                            0.089              
  ACE inhibitors                    No                                231                  Ref                                                  Ref                                                         
                                    Yes                               143                  -0.235 (0.628)   0.709                               0.166 (0.156)                            0.290              
  ARBs                              No                                353                  Ref                                                  Ref                                                         
                                    Yes                               21                   -0.144 (1.169)   0.902                               0.012 (0.307)                            0.968              
  Alpha blockers                    No                                310                  Ref                                                  Ref                                                         
                                    Yes                               64                   2.087 (0.795)    0.009                               -0.048 (0.203)                           0.813              
  Beta blockers                     No                                189                  Ref                                                  Ref                                                         
                                    Yes                               185                  1.410 (0.680)    0.039                               0.107 (0.171)                            0.531              
  Diuretics                         No                                276                  Ref                                                  Ref                                                         
                                    Yes                               98                   -0.010 (0.710)   0.989                               0.020 (0.177)                            0.909              
  Any antihypertensive medication   No                                61                   Ref                                                  Ref                                                         
                                    Yes                               313                  2.378 (0.898)    0.009                               0.497 (0.228)                            0.030              
  **Second visit**                  Calcium channel blockers          No                   327              Ref                                                                          Ref                
                                                                      Yes                  84               0.942 (0.794)             0.236                                              0.307 (0.153)      0.046
                                    ACE inhibitors                    No                   207              Ref                                                                          Ref                
                                                                      Yes                  204              -0.215 (0.657)            0.743                                              0.016 (0.128)      0.899
                                    ARBs                              No                   366              Ref                                                                          Ref                
                                                                      Yes                  45               0.687 (1.084)             0.527                                              -0.285 (0.215)     0.187
                                    Alpha blockers                    No                   329              Ref                                                                          Ref                
                                                                      Yes                  82               0.584 (0.867)             0.501                                              0.032 (0.171)      0.851
                                    Beta blockers                     No                   189              Ref                                                                          Ref                
                                                                      Yes                  222              1.287 (0.715)             0.073                                              0.123 (0.142)      0.388
                                    Diuretics                         No                   270              Ref                                                                          Ref                
                                                                      Yes                  141              0.010 (0.685)             0.989                                              -0.031 (0.136)     0.818
                                    Any antihypertensive medication   No                   36               Ref                                                                          Ref                
                                                                      Yes                  375              2.313 (1.214)             0.058                                              0.430 (0.235)      0.069
  --------------------------------- --------------------------------- -------------------- ---------------- ------------------------- --------- ---------------------------------------- ------------------ ---------

a: Adjusted for covariates at each visit: age + leucocyte distribution (Houseman algorithm) + BMI + smoking status + alcohol consumption + physical activity + years of education + total cholesterol + HDL + triglycerides + fasting glucose + SBP + stroke + CHD + diabetes + cancer + random effect (batch effect of methylation measurement);

b: Additionally adjusted for age acceleration at each visit.

[Table S3a](#SD3){ref-type="supplementary-material"} showed sensitivity analyses for the cross-sectional associations of any AHM use with the AA and Δ~AA~ of Hannum DNAmAge and DNA methylation Phenotypic age (DNAmPhenoAge). Taking any AHMs showed positive correlations with the AA of each biomarker and significantly associated with both forms of AA at the first visit. People who took medications were about 2.2 years/1.7 years older in people compared to the controls, respectively. Even though taking any AHMs was not robustly associated with the Δ~AA~ of neither biomarker, the effects were in the same direction as we identified for the Horvath DNAmAge.

Longitudinal associations of antihypertensive medication with age acceleration and the change rate of age acceleration
----------------------------------------------------------------------------------------------------------------------

We further examined the longitudinal association between AHM use and Δ~AA~ ([Table 4](#t4){ref-type="table"}). People that with continuous medication use were older than that never used (76.6 vs. 73.7 years). After controlling for the potential covariates at the first visit, taking AHM showed positive correlations with the AA and Δ~AA~. Compared to people who never took any AHM, individuals who started to take AHM after the first visit had an increased Δ~AA~ of about 0.3 year/chronological year, and individuals with continuous AHM use had an increased Δ~AA~ of about 0.6 year/chronological year. Consistent with this finding, stopping taking ACE inhibitors, ARBs, and alpha and beta blockers showed negative correlations with Δ~AA~, compared to continuous use. A subgroup analysis among 313 participants with hypertension at first visit yielded a similar pattern ([Table 5](#t5){ref-type="table"}). After fully controlling for potential covariates, stopped taking AHM was correlated with a declining Δ~AA~ compared to the continued AHM use after the first visit albeit not statistically significant.

###### Associations between antihypertensive medication use and change rate of age acceleration from first to second visit.

  --------------------------------- ------------------------------- ---------------- ------------------------------------- --------- -- ---------------- -------
  **Medication**                    **Change of medication use**    **N**            **Change rate of age acceleration**                                 
  **Model 1 ^a^**                                                   **Model 2^b^**                                                                       
  Coefficients(SE)                  p-value                                          Coefficients(SE)                      p-value                       
  Calcium channel blockers          Never used                      440              Ref                                                Ref              
                                    Stopped use after first visit   22               0.103 (0.272)                         0.706        0.264 (0.304)    0.386
                                    Started use after first visit   40               0.437 (0.201)                         0.030        0.405 (0.216)    0.062
                                    Continuous use                  44               0.338 (0.194)                         0.083        0.338 (0.214)    0.116
  ACE inhibitors                    Never used                      327              Ref                                                Ref              
                                    Stopped use after first visit   15               -0.121 (0.316)                        0.701        -0.026 (0.348)   0.942
                                    Started use after first visit   76               -0.081 (0.159)                        0.614        0.033 (0.185)    0.857
                                    Continuous use                  128              0.103 (0.128)                         0.419        0.163 (0.156)    0.297
  ARBs                              Never used                      496              Ref                                                Ref              
                                    Stopped use after first visit   5                -0.223 (0.535)                        0.677        -0.250 (0.556)   0.654
                                    Started use after first visit   29               -0.216 (0.235)                        0.359        -0.145 (0.276)   0.599
                                    Continuous use                  16               -0.006 (0.303)                        0.983        0.011 (0.319)    0.972
  Alpha blockers                    Never used                      442              Ref                                                Ref              
                                    Stopped use after first visit   14               -0.422( 0.325)                        0.195        -0.330 (0.371)   0.375
                                    Started use after first visit   40               0.105 (0.202)                         0.605        0.269 (0.222)    0.226
                                    Continuous use                  50               0.065 (0.185)                         0.727        0.063 (0.201)    0.753
  Beta blockers                     Never used                      300              Ref                                                Ref              
                                    Stopped use after first visit   24               -0.586 (0.268)                        0.029        -0.598 (0.300)   0.047
                                    Started use after first visit   61               0.180 (0.169)                         0.288        0.290 (0.185)    0.117
                                    Continuous use                  161              0.193 (0.122)                         0.114        0.471 (0.164)    0.100
  Diuretics                         Never used                      385              Ref                                                Ref              
                                    Stopped use after first visit   20               0.183 (0.277)                         0.509        0.010 (0.293)    0.972
                                    Started use after first visit   63               -0.017 (0.169)                        0.921        -0.019 (0.186)   0.918
                                    Continuous use                  78               0.068 (0.154)                         0.658        -0.016 (0.181)   0.932
  Any antihypertensive medication   Never used                      150              Ref                                                Ref              
                                    Stopped use after first visit   13               -0.117 (0.374)                        0.754        0.006 (0.433)    0.989
                                    Started use after first visit   83               0.135 (0.168)                         0.422        0.285 (0.185)    0.124
                                    Continuous use                  300              0.258 (0.127)                         0.043        0.596 (0.220)    0.008
  --------------------------------- ------------------------------- ---------------- ------------------------------------- --------- -- ---------------- -------

a: Model 1: Adjusted for: age (first visit) + age acceleration (first visit) + leukocyte distribution (first visit, Houseman algorithm) + random effect (batch effect of methylation measurement at first visit);

b: Model 2: Model 1 + BMI (first visit) + smoking status (first visit) + alcohol consumption (first visit) + physical activity (first visit) + years of education (first visit) + total cholesterol (first visit) + HDL (first visit) + triglycerides (first visit) + fasting glucose (first visit) + SBP (first visit) + hypertension (first visit) + stroke (first visit) + CHD (first visit) + diabetes (first visit) + cancer (first visit).

###### Associations between stopping antihypertensive medication use and change rate of age acceleration among the subpopulation that used the antihypertensive medications at first visit.

  --------------------------------- ------------------------------- ----------------- --------------------------------- --------- -- ---------------- -------
  **Medication**                    **Change of medication use**    **N**             **Changes of age acceleration**                                 
  **Model 1 ^a^**                                                   **Model 2 ^b^**                                                                   
  Coefficients(SE)                  p-value                                           Coefficients(SE)                  p-value                       
  Calcium channel blockers          Stopped use after first visit   22                -0.415 (0.316)                    0.196        -0.143 (0.442)   0.751
                                    Continuous use                  44                Ref                                            Ref              
  ACE inhibitors                    Stopped use after first visit   15                -0.308 (0.322)                    0.342        -0.212 (0.369)   0.567
                                    Continuous use                  128               Ref                                            Ref              
  ARBs                              Stopped use after first visit   5                 -1.724 (0.831)                    0.077        -0.050 (3.331)   0.985
                                    Continuous use                  16                Ref                                            Ref              
  Alpha blockers                    Stopped use after first visit   14                -0.482 (0.294)                    0.109        -0.040 (0.569)   0.945
                                    Continuous use                  50                Ref                                            Ref              
  Beta blockers                     Stopped use after first visit   24                -0.731 (0.333)                    0.030        -0.824 (0.401)   0.042
                                    Continuous use                  161               Ref                                            Ref              
  Diuretics                         Stopped use after first visit   20                0.156 (0.335)                     0.642        -0.263 (0.407)   0.521
                                    Continuous use                  78                Ref                                            Ref              
  Any antihypertensive medication   Stopped use after first visit   13                -0.317 (0.391)                    0.418        -0.585 (0.434)   0.180
                                    Continuous use                  300               Ref                                            Ref              
  --------------------------------- ------------------------------- ----------------- --------------------------------- --------- -- ---------------- -------

a: Model 1: Adjusted for age (first visit) + age acceleration (first visit) + leukocyte distribution (first visit, Houseman algorithm) + random effect (batch effect of methylation measurement at first visit);

b: Model 2: Model 1 + BMI (first visit) + smoking status (first visit) + alcohol consumption (first visit) + physical activity (first visit) + years of education (first visit) + total cholesterol (first visit) + HDL (first visit) + triglycerides (first visit) + fasting glucose (first visit) + SBP (first visit) + hypertension (first visit) + stroke (first visit) + CHD (first visit) + diabetes (first visit) + cancer (first visit).

Same longitudinal tests were also performed for the Δ~AA~ of Hannum DNAmAge and DNAmPhenoAge as sensitivity analyses in [Table S3b](#SD3){ref-type="supplementary-material"}. The Δ~AA~ of neither biomarker showed significant associations with the change of AHM use, but an increasing pattern was still observed for the people with continuous AHMs use in comparison to the people who never used the AHM for each biomarker.

DISCUSSION
==========

In the present study, we investigated the cross-sectional and longitudinal associations of AHM use with the AA of Horvath DNAmAge in a longitudinal study of older male participants examined over two visits. Even though a general decrease of AA was observed between the two visits, after fully adjusting for hypertension and other potential covariates, any AHM use showed a cross-sectional significant association with higher AA at each visit, as well as a longitudinal association with increased Δ~AA~ between visits. Particularly, relative to participants who never took any AHM, individuals with continuous AHM use had a higher Δ~AA~ of 0.6 year/chronological year. Additional sensitivity analyses on another two DNA methylation-based biomarkers (Hannum DNAmAge & DNAmPhenoAge) showed the similar patterns with the use of AHM as the Horvath DNAmAge.

Recently, Marioni et al. found that DNAmAge increases at a slower rate than chronological age across the life course in five independent cohorts, especially in the older population \[[@r21]\], which suggested that, overall, AA declines as people get older. The global decreasing pattern of AA across the two visits observed in our study is in line with this finding. This pattern may also be explained by survival bias, due to the higher probability that healthier participants with relatively lower AA may stay longer in longitudinal studies. After adjusting for hypertension and other potential covariates that might affect the DNAmAge, we surprisingly found that taking AHMs was associated with faster AA. This finding is at variance with the declining pattern of DNAmAge across the lifespan and is not consistent with the preventive effects of AHMs against age-related health outcomes caused by hypertension \[[@r18],[@r19]\]. Several explanations may account for this discrepancy.

First, measurement bias or inaccuracies may affect the comparability of longitudinal AA and Δ~AA~ estimates. Nevertheless, we have restricted this technical bias to the greatest extent by adjusting for the batch of DNA methylation measurement as a random effect and normalizing the methylation profiles with Horvath's internal normalization method. Furthermore, selection bias due to differential survival rate may cause an underrepresentation of participants with higher AA \[[@r22]\], and may lead to underestimation or even contradicting results of the effect of AHM use on AA and Δ~AA~, and distort their associations towards the opposite. In our analyses, we accounted for potential selection bias due to the loss of follow-up using inverse probability weighting (IPW) \[[@r23]\]. Point estimates were similar between models using and not using IPW, indicating that little selection bias was introduced due to the loss to follow-up. Additionally, since the use of AHMs is usually treated as the indicator of hypertension severity, our study might report a proxy outcome that indeed reflected the impact of hypertension on aging (confounding by indication). Due to this concern, despite the weak positive but not significant pattern we observed between hypertension and the AA (Δ~AA~), we additionally adjusted for SBP and hypertension in the fully-adjusted analysis model and performed another sensitivity analysis by adding the interaction term of hypertension and AHMs (data not shown). Neither of the two adjustments altered the patterns of taking AHMs with AA and Δ~AA~ in any relevant manner. In the meanwhile, people might stop taking AHMs after reducing the blood pressure through changing lifestyles and exercises, two factors that are likely to decrease the Δ~AA~. After controlling for the factors, we still observed a declining pattern between stopping taking any AHM and Δ~AA~, albeit not significant due to the limited sample size.

One biologically plausible explanation for this inconsistent observation is a potential causal connection among aging, epigenetic biomarkers of age, hypertension and AHM use. We speculate that in these four-corner relationships, aging independently leads to the change of epigenetic biomarkers of age (e.g., DNAmAge, DNAmPhenoAge) and hypertension via two separate pathways. Aging could cause the change of epigenetic biomarkers of age by altering the methylation levels of age-related CpG sites. In parallel, aging could prompt hypertension via a "vicious cycle", which consists of inflammation, oxidative stress and endothelial dysfunction, and might not be closely related to age-related DNA methylation changes \[[@r16],[@r17]\]. Taking AHMs could control blood pressure and reduce the risks of aging-related diseases, such as CVD, kidney failure and dementia, which are caused by hypertension. Nevertheless, as the causation between aging and hypertension is one-way, reducing blood pressure using AHM might not reversely affect biological aging by bringing the aberrant changes of age-related CpG sites back to normal levels. On the contrary, the AHMs' potential side effects, such as abnormal glucose and lipid metabolism \[[@r24]\] and psychological/cognitive disorders \[[@r25],[@r26]\], might have the potential to accelerate epigenetic biomarkers of age as suggested by previous studies \[[@r6],[@r10],[@r27]\]. However, this hypothesis needs to be evaluated by further research with larger populations and multiple follow-ups along with corresponding causal inferences and functional tests.

It is worth noting that the effects of specific medications on AA and Δ~AA~ were not all unfavorable. In our study, ACE inhibitors, ARBs, and diuretics showed weak negative correlation with AA and Δ~AA~, while beta blockers showed a strong aging accelerating effect. Beyond the effects from specific medications, we should not ignore the adverse drug reactions (ADRs) from combined and inappropriate medication use \[[@r28]\], given most of the participants with hypertension took multiple medications at the same time. ADRs could become more severe and frequent in the elderly due to age-dependent pharmacodynamics and pharmacokinetic changes promoting drug-drug or drug-disease interactions, and such reactions could directly (or indirectly) facilitate the development of aging-related health outcomes including frailty and all-cause mortality \[[@r29],[@r30]\]. This effect might play another key role in accelerating DNAmAge if the ADRs are not identified and treated with further changes in prescriptions.

Major strengths of the present study include the relatively large sample size and repeated measurements with detailed information on a broad range of covariates in a large cohort study. We also acknowledge several limitations in the interpretation of results. First, shifts of leukocyte distribution might affect the DNA methylation changes in whole blood samples \[[@r31]\]. Hence, we adjusted for leukocyte distribution by the Houseman algorithm to restrict potential confounding from differential blood counts to the greatest possible extent \[[@r32]\]. Nevertheless, residual confounding by this and other factors cannot be excluded entirely for the longitudinal analysis. Furthermore, the selected study participants were Caucasians and all male, which limits the generalizability of our results to other racial/ethnic groups and women. Finally, although our overall sample size was relatively large, some of the nonsignificant results may have been due to the lack of statistical power with the relatively smaller size of subsamples for specific AHMs. And given those subgroup analyses did not appear as robust as the whole population and showed contradicted patterns, there might be a risk of getting false positive findings, further research with a bigger sample size and longer multiple follow-ups are warranted to validate our results by eliminating the possibility of false positives.

In summary, we observed cross-sectional and longitudinal associations of any AHM use with increased AA and Δ~AA~. Our findings suggest that controlling blood pressure by taking medications might not be able to reduce the accelerated epigenetic aging, on the contrary, was associated with accelerated DNAmAge. This study partly reveals the relationship between AHMs and biological aging, and also underlines that DNAmAge and AA may not be able to capture the preventive effects of AHMs that reduce cardiovascular risks and mortality. Future investigations are required to confirm our findings and to elucidate the causal relationship between AHM use and DNAmAge, as well as the underlying pathophysiological mechanisms.

MATERIALS AND METHODS
=====================

Study design and population
---------------------------

The NAS study is an ongoing longitudinal study of aging, established by the U.S. Department of Veterans Affairs in 1963. Details of this study have been published previously \[[@r33]\]. Briefly, the NAS is a closed cohort of 2,280 male veterans from the Greater Boston area. They were enrolled after an initial health screening that determined that they were free of known chronic medical conditions. Blood samples were collected from 657 participants, most of whom were visited up to 4 times between 1999 and 2013. Participants have been reevaluated every 3--5 years on a continuous rolling basis using detailed on-site physical examinations and questionnaires. We restricted the current analysis to the data of the first two visits of 546 Caucasian participants (aged 55-85 years) who had been visited twice at least, in order to control for the heterogeneity of race and to analyze the change of AA longitudinally. The NAS study was approved by the Department of Veterans Affairs Boston Healthcare System, and written informed consent was obtained from each subject prior to participation.

Data collection
---------------

As previously described \[[@r34]\], at each visit, participants were asked to provide detailed information about their lifestyles, dietary habits, activity levels, and demographic factors. Height and weight were measured and were used to calculate body mass index (BMI, in kg/m^2^). Blood samples were collected for assessing blood-based biomarkers. Participants' status of major diseases was assessed based on the medical history and physicians' diagnosis. In particular, hypertension was defined as a measured SBP of ≥140 mmHg, a measured diastolic blood pressure (DBP) of ≥90 mm Hg, or participants' use of AHMs \[[@r35]\]. SBP and DBP were measured by a physician, and the AHMs included calcium channel blockers, ACE inhibitors, ARBs, alpha blockers, beta blockers and diuretics.

DNA methylation data
--------------------

DNA of whole blood samples were collected between 1999 and 2013. As previously described \[[@r36],[@r37]\], we used the QIAamp DNA Blood Kit (Qiagen, CA, USA) to extract DNA from buffy coat, and performed bisulfite conversion with the EZ-96 DNA Methylation Kit (Zymo Research, CA, USA). To minimize batch effects, we randomized chips across plates and randomized samples based on a 2-stage age-stratified algorithm so that age distributed similarly across chips and plates. We measured DNA methylation of CpG probes using Illumina HumanMethylation450 BeadChip for all the samples from both visits. After quality control, the remaining samples were preprocessed using the Illumina-type background correction, dye-bias adjustment and BMIQ normalization \[[@r38]\], which were used to generate methylation status. The methylation status of a specific CpG site was quantified as a β value ranging from 0 (no methylation) to 1 (full methylation).

A total of 353 CpG sites were retrieved from the methylation profiles for the estimation of DNAmAge for each participant based on the algorithm proposed by Horvath \[[@r3]\]. This algorithm was derived from a range of tissues and cell types using 353 probes targeted in the Illumina 27k and 450k methylation arrays. In this study, we performed the estimation by using the online calculator, where background-corrected beta values were pre-processed by the calculator's internal normalization method \[[@r3]\]. AA was determined as discrepancies between methylation and chronological age in the form of residuals, which have a mean of 0 and represent positive and negative deviations from chronological age in years. The residuals were calculated by a linear regression procedure in which DNA methylation age was the outcome and chronological age was the independent variable. The Δ~AA~ for each participant between the two visits was determined as:

Δ

AA

=

AA of second visit (year) - AA of first visit (year)

Time between first and second visit (year)

with a unit of year/chronological year.

Statistical analysis
--------------------

Study population of each visit was described with respect to major socio-demographic characteristics, lifestyle factors and detailed AHM use. The correlation between estimated DNAmAge and chronological age at each visit was evaluated by Spearman correlation coefficient.

We first tested the cross-sectional association of hypertension with AA at each visit and the Δ~AA~ between the two visits. A linear mixed model with AA (Δ~AA~) as outcome was employed, controlling for covariates that have been reported to be associated with DNA methylation changes or with the use of AHM, including age (years), BMI \[kg/m^2^, underweight (\<18.5, \< 1% of the study population) or normal weight (18.5 to \<25), overweight (25 to \<30), obese (≥30)\], alcohol consumption \[abstainer, low (0 to \<40 g/d), intermediate (40 to \<60 g/d), high (≥60 g/d)\], smoking (current/ former/ never smoker), education (≤12 years, 13 -- 16 years, \>16 years), physical activity \[metabolic equivalent of task (MET), low (≤12 kcal/kg hours/week), median (12--30 kcal/kg hours/week), high (≥30 kcal/kg hours/week)\] and leukocyte distribution (Houseman algorithm \[[@r32]\]). The batch of microarray experiments in DNA methylation measurement was controlled for as the random effect. Corresponding AA was additionally adjusted for in the analyses of Δ~AA~ at each visit.

We then investigated the cross-sectional associations of AHM use with AA and Δ~AA~ at each visit in two mixed linear regression models. Model 1 adjusted for age, leukocyte distribution and the random batch effect, and Model 2 further adjusted for BMI, smoking status, alcohol consumption, physical activity, education, total cholesterol (mg/dL), HDL (mg/dL), triglycerides (mg/dL), fasting glucose (mg/dL), SBP (mm Hg), hypertension, stroke, coronary heart disease, diabetes and cancer (yes/no). AA was additionally adjusted for in the analyses of Δ~AA~ at each visit.

Finally, we examined the longitudinal association between AHM use and the Δ~AA~. AHM use in the longitudinal analysis was classified as: never used, stopped use after first visit, started use after first visit and continuous use according to the reports of AHM use between the two visits, and was treated as a predictor in the analysis models. Two mixed linear regression models were used, adjusting for the same covariates described above.

Sensitivity analyses
--------------------

We further performed sensitivity analyses for the main results by using another two DNA methylation based aging biomarkers: DNAmAge estimated by Hanumm et al.'s algorithm \[[@r39]\], and DNAmPhenoAge recently developed by Morgan et al. as an "update" of the Horvath DNAmAge for the lifespan \[[@r40]\].

Hanumm DNAmAge was estimated based on 71 age-related CpG sites reported in 2013 \[[@r39]\] and determined as the sum of the methylation beta values multiplied by the reported effect sizes of the predictors. AA of Hannum's DNAmAge was also determined as discrepancies between DNA methylation and chronological age in the form of residuals.

Another batch of 513 CpG sites was retrieved for the estimation of DNAmPhenoAge for each participant based on the algorithm proposed by Levine et al. \[[@r40]\]. With the coefficient and intercept values provided by the authors, we estimated the DNAmPhenoAge as:

DNAmPhenoAge = 𝐶𝑝𝐺
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× 𝛽

1
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+⋯ 𝐶𝑝𝐺
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× 𝛽
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As defined by the authors \[[@r40]\], difference between Phenotypic and chronological age (DNAmPhenoAge -- chronological age) was defined as the AA of DNAmPhenoAge. The Δ~AA~ for the two aging biomarkers between the two visits was also determined by the [formula (1)](#e1){ref-type="disp-formula"}.

We tested the cross-sectional and longitudinal associations of the AA and Δ~AA~ of the two biomarkers with the use of any AHM using the same analysis models employed in the main analyses for Horvath DNAmAge.

Data cleaning and all aforementioned analyses were performed by SAS version 9.4 (SAS Institute Inc., Cary, NC, USA), and all statistical tests were two-sided with p-values of \<0.05.
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